

## Indian firm Intas Pharma makes breakthrough in antifungal therapy domain

13 October 2021 | News

### Launches world's first SB-100mg Itraconazole



Intas Pharmaceuticals, based in India, has made a progressive breakthrough in the Antifungal Therapy domain with the launch of the world's first Super Bioavailable Itraconazole-SB 100mg by the Brand Name of Itaspor-SB Forte/Subawin. It has been recently approved by Indian Regulatory Authorities.

Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage, antacids consumption etc. and overall cost of treatment.

Itaspor SB Forte/Subawin is expected to improve patient compliance and reduce the Doctor's counselling time. It will reduce dosing to half. Furthermore, patients can take it with or without a meal with just water or as directed by the physician. The cost of the therapy is also reduced substantially.

"Intas' newest formulation within the 25 year old brand Itaspor is formulated with Super Bioavailable (SB) Technology that makes 1 Itaspor-SB Forte capsule equivalent to conventional 200mg Itraconazole," said DrAlok Chaturvedi, Senior Vice-president & Head - Medical Affairs, Intas Pharmaceuticals.